[3-hydroxy-10,13-dimethyl-17-[1-(5-methylpiperidin-2-yl)ethyl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-16-yl] acetate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [3-hydroxy-10,13-dimethyl-17-[1-(5-methylpiperidin-2-yl)ethyl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-16-yl] acetate
• 化学式: C₂₉H₄₇NO₃
• 分子量: 457.7
• InChiKey: ZVYUDNWAHWVPPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Isolation of Cyclopamine
  申请人：Infinity Pharmaceuticals, Inc.

  公开号：US20160168193A1

  公开（公告）日：2016-06-16

  Provided are deglycosylation methods designed to optimize the yield of a Veratrum alkaloid from Veratrum plant material and/or from an extract of Veratrum plant material.

  提供了去糖化方法，旨在优化从鸢尾科植物材料和/或从鸢尾科植物材料提取物中提取鸢尾科生物碱的产量。
• Regulators of the hedgehog pathway, compositions and uses related thereto
  申请人：Beachy A. Philip

  公开号：US20060128639A1

  公开（公告）日：2006-06-15

  The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.

  本发明提供了调节平滑蛋白依赖性通路激活的方法和试剂等。在某些实施例中，这些方法可用于对抗由于刺猬增强功能、ptc失去功能或平滑蛋白增强功能突变引起的刺猬通路不必要激活的表型效应。
• Diversion- and/or abuse-resistant aompositions and methods for making the same
  申请人：Losev Mikhail Viktorovich

  公开号：US20110207761A1

  公开（公告）日：2011-08-25

  A composition formulated for diversion- and/or abuse-resistance, includes at least one active pharmaceutical ingredient (API), each present in an acidic form, a first compound capable of coupling to the acidic form of the API to form a complex, where the resulting complex is resistant to separation by conventional separation methods, and a second compound capable of preferentially coupling to the first compound to thereby release the API from the complex.

  一种旨在防止滥用和/或耐受性的组合物，包括至少一种活性药物成分（API），每种API以酸性形式存在，第一化合物能够与API的酸性形式偶联形成复合物，所得到的复合物对传统的分离方法具有耐受性，以及第二化合物能够优先与第一化合物偶联，从而释放复合物中的API。
• Diversion - And/Or Abuse-Resistant Compositions And Methods For Making The Same
  申请人：Invincible Biotechnology, LLC

  公开号：US20150335593A1

  公开（公告）日：2015-11-26

  A composition formulated for diversion- and/or abuse-resistance, includes at least one active pharmaceutical ingredient (API), each present in an acidic form, a first compound capable of coupling to the acidic form of the API to form a complex, where the resulting complex is resistant to separation by conventional separation methods, and a second compound capable of preferentially coupling to the first compound to thereby release the API from the complex.

  一种旨在防止滥用和/或耐受性的配方，包括至少一种活性药物成分（API），每种成分以酸性形式存在，第一化合物能够与API的酸性形式偶联形成复合物，所得复合物对常规分离方法具有耐受性，第二化合物能够优先与第一化合物偶联，从而释放复合物中的API。
• Use of a decoy protein that interferes with the hedgehog signalling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
  申请人：Fondazione Telethon

  公开号：EP2123306A1

  公开（公告）日：2009-11-25

  The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/ or reversing ocular diseases related with ocular neovascularization. Partcularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).

  本发明涉及使用干扰刺猬信号通路的化合物来制造预防、抑制和/或逆转与眼部新生血管相关的眼部疾病的药物。部分上述疾病是（湿性）老年性黄斑变性、（增殖性）糖尿病视网膜病变、新生血管性青光眼、视网膜静脉闭塞或早产儿视网膜病变（ROP）。